One to watch

The company has been a sluggish counter for some time but this could be about to change as some of its dozen or so projects begin to become revenue-generating. Since the end of the latest reporting period, Eredene closed a successful bid for the concession to develop the container terminal in the port of Ennore and the acquisition of a stake in Ocean Sparkle, a port services company. These support Eredene's existing portfolio of interests in port and related activities, which are key elements in the Indian government's drive to modernise the country's infrastructure.

True, for prospective investors the lack of a dividend distribution for the foreseeable future, and the real possibility that the company may require further funds to develop its investment portfolio, might inhibit near-term progress but for those who believe in India's growing importance on the world stage Eredene Capital could be a stock worth monitoring.

• The value of your investment could fall and you may get back less than you invested. You should take professional advice if you have any doubt about the suitability of this stock for your portfolio.

Eredene Capital

20p unch

Scotsman says BUY

BROKER SNAPS

ProStrakan

74.75p -1.25p

Broker says BUY

AHEAD of drug maker ProStrakan's interim results on Thursday, Numis has reiterated its "buy" recommendation. The broker said: "We anticipate continued strong momentum in European sales, combined with updates on US approvals. All the regulatory 'bad news' is (already] in the price."

Oxford Catalysts

81.25p +7.25p

Broker says BUY

KBC Peel Hunt said that Oxford Catalysts' technology has passed another hurdle, with the first "demonstration of performance" achieved. This should now lead to the first commercial order, said KBC, adding: "Evidence of traction in a large and potentially highly profitable market is key to the investment case."